Constitutive expression of MAP kinase phosphatase-1 confers multi-drug resistance in human glioblastoma cells

Cancer Research and Treatment

Volumn 44, Issue 3, 2012, Pages 195-201

  Yu, Hana ^a   Park, Junseong ^a   Lee, Jungsul ^a   Choi, Kyungsun ^a   Choi, Chulhee ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

Anti cencer drug resistance; Apoptosis; Chemotherpy; Dual specificity phosphatase 1; Glioblastoma; JNK mitogen activated protein kinases

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; MITOMYCIN; STRESS ACTIVATED PROTEIN KINASE; VINCRISTINE;

ARTICLE; ASTROCYTE; CANCER RESISTANCE; CELL VIABILITY; CONCENTRATION RESPONSE; DRUG CYTOTOXICITY; ENZYME SPECIFICITY; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA ISOLATION; TRANSIENT TRANSFECTION; TUMOR RESISTANCE;

EID: 84874087852     PISSN: 15982998     EISSN: 20059256     Source Type: Journal    
DOI: 10.4143/crt.2012.44.3.195     Document Type: Article

References (22)

1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492-507.
2. Meyer MA. Malignant gliomas in adults. N Engl J Med. 2008;359:1850.
3. Krakstad C, Chekenya M. Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol Cancer. 2010;9:135.
4. Reijneveld JC, Voest EE, Taphoorn MJ. Angiogenesis in malignant primary and metastatic brain tumors. J Neurol. 2000;247:597-608.
5. Bredel M, Zentner J. Brain-tumour drug resistance: the bare essentials. Lancet Oncol. 2002; 3:397-406.
6. Wick W, Weller M, Weiler M, Batchelor T, Yung AW, Platten M. Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro Oncol. 2011;13:566-79.
7. Riemenschneider MJ, Hegi ME, Reifenberger G. MGMT promoter methylation in malignant gliomas. Target Oncol. 2010;5:161-5.
8. Bredel M. Anticancer drug resistance in primary human brain tumors. Brain Res Brain Res Rev. 2001;35:161-204.
9. Patterson KI, Brummer T, O'Brien PM, Daly RJ. Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J. 2009;418:475-89.
10. Bermudez O, Pages G, Gimond C. The dual-specificity MAP kinase phosphatases: critical roles in development and cancer. Am J Physiol Cell Physiol. 2010;299:C189-202.
11. Keyse SM. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev. 2008;27:253-61.
12. Small GW, Somasundaram S, Moore DT, Shi YY, Orlowski RZ. Repression of mitogenactivated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44/42-MAPK. J Pharmacol Exp Ther. 2003;307:861-9.
13. Small GW, Shi YY, Edmund NA, Somasundaram S, Moore DT, Orlowski RZ. Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role. Mol Pharmacol. 2004;66:1478-90.
14. Wang J, Zhou JY, Wu GS. ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells. Cancer Res. 2007;67:11933-41.
15. Loda M, Capodieci P, Mishra R, Yao H, Corless C, Grigioni W, et al. Expression of mitogenactivated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. Am J Pathol. 1996;149:1553-64.
16. Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet. 2008;40:600-8.
17. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5:219-34.
18. Wang Z, Xu J, Zhou JY, Liu Y, Wu GS. Mitogen-activated protein kinase phosphatase-1 is required for cisplatin resistance. Cancer Res. 2006;66:8870-7.
19. Small GW, Shi YY, Higgins LS, Orlowski RZ. Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res. 2007;67:4459-66.
20. Chamberlain MC. Bevacizumab for the treatment of recurrent glioblastoma. Clin Med Insights Oncol. 2011;5:117-29.
21. Jakobsen JN, Hasselbalch B, Stockhausen MT, Lassen U, Poulsen HS. Irinotecan and bevacizumab in recurrent glioblastoma multiforme. Expert Opin Pharmacother. 2011;12:825-33.
22. Watanabe K, Kanaya H, Fujiyama Y, Kim P. Combination chemotherapy using carboplatin (JM-8) and etoposide (JET therapy) for recurrent malignant gliomas: a phase II study. Acta Neurochir (Wien). 2002;144:1265-70.